GNS
NEUTRALGenus plc Announces Director/PDMR Shareholding
The healthcare company has announced the granting of restricted share units to its executive team under a long-term incentive plan.
Genus
2,590.00GBX
-2.26%
Market Cap
1.72B
Volume
72.89k
45% of avg
P/E Ratio
30.07
EPS (TTM)
86.13
Beta
0.77
Day Range
2,595.00p - 2,666.73p
52 Week Range
1,424.00p2,590.00p3,228.80p
2,590.00p
Upcoming Events
2026
Transaction expected to complete, subject to Chinese regulatory approvals
High Impact Event
26 February 2026
Announcement of interim results for the six month period from 1 July 2025 to 31 December 2025
High Impact Event
GNS
NEUTRALGenus Appoints New Non-Executive Directors
The healthcare company has appointed two new Non-Executive Directors with expertise in human resources and agricultural research and development.
GNS
GOODGenus Delivers Strong Start to the Year
The animal genetics company reports a strong start to the year, with its PIC segment driving robust growth. However, the ABS division has seen slightly lower than expected profit performance.
GNS
NEUTRALGenus plc Notifies Major Shareholding Change
The biotechnology company has received notification of a change in major shareholding.
GNS
NEUTRALGenus plc Announces Annual General Meeting Details
The healthcare company has announced details for its upcoming Annual General Meeting, including the date, time, and location.
GNS
NEUTRALGenus Plc Director Exercises Options
The healthcare company's CEO has exercised share options and sold a portion of the resulting shares.
GNS
NEUTRALGenus Director Increases Shareholding
The healthcare company's Chief Corporate Development Officer has purchased additional shares in an Individual Savings Account.
GNS
NEUTRALGenus Director Sells Shares
The Chief Corporate Development Officer of the biotechnology company has sold 700 shares held in an Individual Savings Account.
GNS
NEUTRALGenus Executives Exercise Share Options
The healthcare company's executives have exercised share options and sold some of the resulting shares.
GNS
NEUTRALGenus Grants Shares to Executives Under Incentive Plans
The healthcare company has granted share awards to its executives under long-term incentive plans.